Risk Factors Are Frequently Inadequately Treated in Patients With Stroke or TIA – Neurology Advisor

Posted on by

In patients with ischemic stroke and transient ischemic attack (TIA) there is a significant gap between evidence-based cerebrovascular risk factors control and real-world stroke prevention, according to study results published in Neurology.

Whileprevious studies have found poor lifestyle and modifiable risk factors arecommon in patients with ischemic stroke, limited data are available on riskfactor control in patients with stroke/TIA.The goal of the study was to assess the prevalence of inadequatelytreated risk factors in a large cohort of patients with stroke/TIA.

The observational cohort study included patients from the Poststroke Disease Management STROKE-CARD trial (ClinicalTrials.gov Identifier: NCT02156778). Of 2625 adult patients with acute ischemic stroke or TIA admitted to the University Hospital Innsbruck, Austria, between January 2014 and December 2017, the study population comprised 1730 patients (median age 72 years, 59.6% men), including 1424 stroke patients and 306 patients with TIA. Of these, 1382 were first-ever strokes/TIAs.

Overall,79.5% of subjects had at least one inadequately treated stroke risk conditionbefore the index event. Hypercholesterolemia (53.4% of the study population)and hypertension (45.7%) were the most common risk factors, followed by atrialfibrillation (12.5%), previous atherosclerosis cardiovascular disease (12.4%),diabetes mellitus (9.9%), unrecognized TIA (2.7%), carotid stenosis (2.1%), andmechanical heart valves (0.5%).

Whenmodifiable lifestyle risk behaviors were included as inadequately-treated riskfactors, the percentage of subjects with at least 1 inadequately treated strokerisk condition before the index event was 95.1%. Many subjects had more than 1uncontrolled risk factor (eg, 72.3% had at least 2 inadequately treated riskfactors).

Thenumber of inadequately treated risk factors was higher in patients withrecurrent stroke/TIA, compared with patients with first-ever events (P <.001),in younger patients (75 years) compared with patients >75 years of age (P<.001), and in male patients (P =.003).

Assessmentof stroke preventability with adequate risk factors control revealed that bloodpressure control could have prevented 237 events (13.7%), while rigorous lipidprofile control could have prevented 182 events (10.5%) and properanticoagulation in patients with pre-diagnosed atrial fibrillation could haveprevented 145 events (8.4%). On theother hand, the estimated degree of stroke preventability with adequateanticoagulation in patients with mechanical heart valves was low (0.4%).

Forthe 5 most relevant risk factors combined (hypertension, hypercholesterolemia, atrialfibrillation, smoking, and overweight), the estimated degree of strokepreventability was 1 in 2, assuming an additive effect, and 1 in 4 with ahighly conservative computation approach.

Thestudy had several limitations, according to the researchers, including lack ofconsensus on the definition of adequate control of risk factors, missinginformation on pre-stroke blood pressure profiles, lack of valid way to assessthe quality of diet and physical activity.

Population-widecampaigns, individualized prevention and poststroke disease managementprograms, and an increased awareness among physicians about the concept ofstroke preventability are required to reduce the global burden of stroke,conclude the researchers.

Reference

Boehme C, Toell T, Mayer L, et al. The dimension of preventable stroke in a large representative patient cohort. [published online Oct 31, 2019]. Neurology. doi:10.1212/WNL.0000000000008573

Go here to see the original:
Risk Factors Are Frequently Inadequately Treated in Patients With Stroke or TIA - Neurology Advisor

Omarosa: Something Neurological Going on with Trump His Ignorance Is Destroying America – Breitbart

Posted on by

Former Apprentice cast member and former White House staffer Omarosa Manigault Newman declared on Sundays broadcast of MSNBCs Weekends there was something neurological going on with President Donald Trump.

Manigault Newman said, I think its time for us to ring the alarm that Donald Trump is dangerous, and he is damaging our democracy.

She added, There is something neurological going on with Donald Trump. I am not a doctor, but Ill tell you what I observed in 2003 when I first met the man and when I last spoke to him. There is some disconnect with his ability to process basic information. Its not that he doesnt know the basic terminology of the government, of its structure and functions. He makes statements that have impact around the world. Thats what he doesnt grasp. His ignorance is destroying our country.

Follow Pam Key on Twitter @pamkeyNEN

Continued here:
Omarosa: Something Neurological Going on with Trump His Ignorance Is Destroying America - Breitbart

Scientists Have a Fascinating New Map of the Human Brain on DMT – VICE

Posted on by

Taking DMT is a bit like putting your brain through a jet engine and getting your consciousness blown out the other side. Theres no you anymore. Youre just kind of everywhere, surrounded by colours and fractals and aliens that look a bit like elves. It feels a lot like being dead, or what you imagine being dead feels like, and then youre sucked back into your body feeling somewhere between terrified and peaceful. But whats weird is that for such a chaotic ride, there seems to be a pattern to the experience. The trip tends to follow a similar trajectory each time, and everyone seems to experience some variation of the same thing.

For scientists this uniformity presents some interesting questions. Namely: whats the neurology behind DMT? And why do so many people report seeing elves? These questions have instigated a few studies, including one at Johns Hopkins in the United States, but the latest findings have just come from the Imperial College London.

Last week a study published in Scientific Reports looked at the brains response to DMT, courtesy of the colleges Psychedelic Research Group. There, researchers administered intravenous DMT to 13 subjects, while measuring their brains electrical activity via a web of electrodes loaded into head capsdevices that are known as "EEG caps".

If were serious about understanding human beings and their consciousness, we need to understand psychedelic experiences, Christopher Timmins, a PhD student at Imperial College London and author of the study, told VICE over the phone. DMT [is] particularly relevant because, at normal doses, it generates this very strong sense of immersiveness.

We asked Christopher what else he and his team discovered about DMTs bewildering effects on the brain.

Christopher Timmermann. Credit: Imperial College London, photo by Thomas Angus

VICE: HI Chris. Can you start by explaining our current understanding of how DMT works on a neurological level?Christopher Timmermann: We know DMT works with the serotonin system in the brain. Serotonin is one of the major chemicals that we have in the brain thats responsible for a series of functions related to consciousnesswakefulness, attention. DMT is very closely related to the serotonin molecule. We also know that if you block a specific serotonin receptor in the brain, the psychological effects of DMT are inhibited. So we know that the specific receptor, the serotonin 2A receptor, is crucial for psychedelic effects. And this receptor is expressed all over the cerebral cortexits very prominent in sensory areas, and its distributed all around.

What neurological effects did you see in your subjects after theyd taken DMT? The brainwave patterns seen are particularly notorious in certain states of consciousness. For example, you have an Alpha wave pattern thats very prominent when you close your eyes and disengage from the environment. When we open our eyes after that, this Alpha wave pattern goes down a very significant way. In the DMT study, we found the same thinga very strong reduction of these Alpha waves. The only difference is that people kept their eyes closed. It's almost as if people were seeing with their eyes closed, engaging with a world. And we found this reduction in Alpha waves was very strongly associated [with] the intensity of the experience.

Another way we try to understand brain activity is to see how chaotically, or entropically, the brain behaves after we administer these drugs. With DMT, we found that there was a huge increase in this chaotic activity. This is interesting because its the opposite of what happens in the brain when there is a loss of consciousness, such as when youre in a coma, or youre sleeping or dreaming.

Were there any other brainwave patterns you noticed?Yeah we also saw an increase in Theta and Delta waves. Its interesting because these increases were particularly noticeable when people were in the peak of this experience, so the moment in which people felt completely immersed in this alternate reality of sorts. This Theta wave, specifically, is tightly related to dreaming, so therefore we have some initial evidence that theres a similar mechanism behind dreaming and this very immersive DMT experience.

Treatment room setup. Credit: Imperial College London and photo by Thomas Angus

Im interested in how the people in your study reacted to the DMT. You write that they were all exposed to psychedelics, but did anyone report seeing anything interesting during their trip?There were challenging moments for sure; moments where people in the interview after reported that it was too much. One participant said she reached a point in which she couldnt go further. She described encountering some beings or entities that were pushing against her, not allowing her to trespass into their realm, and I think this was particularly challenging. But after that, she said she was falling through pink clouds of comfort, and other entities were healing her once she was going through this space.

Now, the whole idea is DMT allows people to break through different realities. But it's fairly well established that while some can, others cant. Is there any neurological reason as to why this is?There are many factors that can influence this. Id say a very important one is that people usually smoke DMT, and smoking is a very ineffective way to ingest a drug because a lot of the product can be burned before its absorbed. Theres variability in the lung capacity people have, how much time theyre holding the smoke in, and basically, your history with smoking other substances.

Okay, but are there any explanations neurologically? You mentioned serotonin earlier, so could anything be altering those receptors, like antidepressant drugs for example? We dont know how well antidepressants interact, at least at the experiential level. The usual saying of psychedelics is that when people are taking antidepressants, psychedelics dont work as well. Theres also some evidence that this serotonin 2A receptor is mediated by a gene some people apparently have or dont have. But again, these things are speculative. Theres nothing mechanistically proven about why people may not break through. But I would say that dose is a very big explanation.

Is there any scientific way to explain DMT breakthroughs? Like, are we closer to understanding why, or how, people meet entities like machine elves?At the moment we dont know. What were doing now is were conducting other experiments in which we use DMT, and we give it inside fMRI scanners, because fMRI scanners allow you to look at things happening [inside] the brain with much more precision. And that is important because we know that certain areas of the brain are used for recognising faces, when were engaging in social activities, and so on.

So youre saying DMT might affect the parts of our brain that recognise faces, which could be why were seeing the faces of elves when were on DMT? Look, DMT might be acting on specific areas of the brain responsible for face recognition, or understanding the mind of others, or recognising intentions, but these are speculations only.

So, to you, whats been the point of the study? How has this research helped us to understand DMT or even this notion of consciousness? An important part of this study has been exploring how DMT trips are part of the human experience repertoire. These are states that human beings can have. As a scientist, theres a natural curiosity in understanding not only why, but understanding the experiences themselves. One of the important things about this study has been examining what kind of experiences human beings can have, and how we can make sense of them.

Interview by Sam Nichols. He's on Twitter

This article originally appeared on VICE AU.

Follow this link:
Scientists Have a Fascinating New Map of the Human Brain on DMT - VICE

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Scl | PROM – Dove Medical Press

Posted on by

Osman Ozel,1 Caila B Vaughn,1 Svetlana P Eckert,1 Dejan Jakimovski,2 Alexis A Lizarraga,1 Bianca Weinstock-Guttman1

1Jacobs MS Center for Treatment and Research, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA; 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA

Correspondence: Bianca Weinstock-GuttmanJacobs MS Center for Treatment and Research, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 1010 Main Street, 2 nd Floor, Buffalo, NY 14202, USATel +1 716 829 5063Fax +1 716 829 4001Email bw8@buffalo.edu

Abstract: Dimethyl fumarate (DMF) is a commonly prescribed oral medication for the treatment of relapsing forms of multiple sclerosis (MS) with a wide range of hypothesized downstream mechanisms of action. Randomized clinical trials have established its clinical efficacy by using standard objective clinical measures. However, MS is a chronic disease that, apart from physical ailments, can affect an individuals mood, psychosocial status, and quality of life which cannot be captured by using only objective assessment tools. Given the challenge of determining the efficacy of the treatment in a real-world clinical setting, the use of patient-reported outcomes (PROs) may help us to better address these aspects of patient care and establish a more patient-centered approach to MS care. To date, a review of PubMed identified six studies which reported on PROs in patients who are taking DMF. In total, twelve different kinds of PRO measures were utilized and 6359 patients provided at least one form of PRO in these studies. Upon review of these studies, we were able to conclude that people with MS had decreased quality of life compared to the healthy population in the US. MS patients on DMF, however, had better health-related quality of life assessment scores compared to those using a placebo. Previous studies also suggested that DMF decreased work productivity impairment scores after one year of use compared to baseline. DMF was associated with less impairment in fatigue and depression scales along with improved treatment quality assessment and adherence scores. This review will present a brief synopsis of the published literature and will provide indications for future directions with respect to PROs and DMF in people with MS.

Keywords: multiple sclerosis, patient-reported outcomes, outcome measures, quality of life, dimethyl fumarate

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Scl | PROM - Dove Medical Press

Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board – Business Wire

Posted on by

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced Friedreichs ataxia (FA) as the therapeutic indication for the companys first neurology development program. Exicure also announced the expansion of its Scientific Advisory Board.

Over the past year Exicure has developed extensive preclinical data supporting the development of our SNAs for neurological disorders. Were eager to evaluate our technology for this important unmet medical need, said David Giljohann, PhD, Exicures chief executive officer. We are also pleased to add the experience and team from the Friedreichs Ataxia Research Alliance (FARA), added Dr. Giljohann.

Patients living with FA experience a devastating and progressive loss of neurological function. There are no approved therapies for FA. Exicures FA program will be designed and developed with guidance from and in collaboration with FARA.

"FA is a rare, progressive and life-shortening disease, and there is a critical need for effective treatments," explained FARA's Chief Executive Officer, Jennifer Farmer. "Exicures SNA technology is unique in its ability to target the affected gene in FA. FARA has championed collaborative approaches to drug development, and were thrilled to work with Exicure as they develop their genetically targeted therapeutic candidate.

Exicure expects IND-enabling work to begin in 2020. Exicures preclinical data in rodents and non-human primates showed distribution of SNAs to all brain regions following intrathecal administration, including those relevant in FA. Additional preclinical rodent data, in a head-to-head comparison with an FDA-approved oligonucleotide, nusinersen, showed improved potency in mice when put into an SNA format.

Exicure also is announcing the expansion of the companys Scientific Advisory Board to include neurology experts Dr. Susan Perlman, MD, Professor of Neurology at University of California Los Angeles and Medical Director for the National Ataxia Foundation and Dr. Hank Paulson, MD, PhD, Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan.

We are pleased to bring together this fantastic group of patient advocates, medical leaders, and disease experts to join the Exicure team in our mission to launch a program in Friedreichs ataxia, Dr. Giljohann concluded.

About Friedreichs Ataxia (FA)

FA is a rare, degenerative, life-shortening neuro-muscular disorder that affects children and adults, and involves the loss of strength and coordination usually leading to wheelchair use; diminished vision, hearing and speech; scoliosis (curvature of the spine); increased risk of diabetes; and a life-threatening heart condition. There are no FDA-approved treatments. An estimated 5,000 patients in the US and 15,000 patients worldwide are affected by FA.

About FARA

The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia. http://www.CureFA.org

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.

For more information, visit Exicures website at http://www.exicuretx.com.

Exicure Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Companys technology, potential therapies and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, plan, believe, intend, look forward, and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicures pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Furthermore, data from preclinical studies in mice often fails to be indicative of outcomes in human trials. Risks facing the Company and its programs are set forth in the Companys filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

More:
Exicure Announces First Neurological Development Program in Friedreich's Ataxia and Expands Scientific Advisory Board - Business Wire

American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute…

Posted on by

NETANYA, Israel, Nov. 8, 2019 /PRNewswire/ --Theranica Bio-Electronics Ltd., a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the American Headache Society published an article in its peer-reviewed journal, Headache: The Journal of Head and Face Pain, highlighting the promise of Remote Electrical Neuromodulation (REN) as an alternative to current treatment options and as a potential first-line therapy for acute migraine relief.

"While migraine is one of the most prevalent and disabling neurological diseases affecting a significant portion of the global population, many are still looking for an effective, long-term treatment option," said Alan Rapoport, M.D. author of the article and Professor of Neurology at UCLA. "For the first time, REN offers an effective, safe and non-invasive alternative for acute migraine treatment and may be suitable as a first-line therapy for some users."

The article Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine, reviews a pilot study and a pivotal study conducted to determine the safety and efficacy of the Nerivio, Theranica's smartphone-connected prescription migraine wearable device. Both studies showed positive results, demonstrating REN is as effective a treatment for acute treatment of migraine as standard pharmacological treatments, with a favorable safety profile.

The Nerivio alleviates migraine symptoms by stimulating the body's Conditioned Pain Modulation (CPM) response, in which one painful stimuli modulates pain in other regions of the body. As a smartphone-connected wearable, users can individually control the strength of their therapy and easily share data collected with healthcare providers to improve treatment plans.The Nerivio is the first device to use REN to stimulate CPM by placing the device on the upper arm at the onset of a migraine episode.

"The future of migraine care lies in non-invasive, drug free technologies that are effective and affordable," said Alon Ironi, CEO and co-founder of Theranica. "For those living with migraine, the search for long-term symptom relief is not easy. REN opens the door for new therapeutic alternatives, with Nerivio leading the way."

The article will be published in Headache's print journal in the coming weeks.

About Theranica

Theranica Bioelectronics, founded in 2016, is dedicated to combining advanced neuromodulation therapy with modern wireless technology to develop proprietary electroceuticals that address prevalent medical conditions and diseases. Nerivio, Theranica's first FDA authorized to market device is a low-cost, low side effect wearable for the acute treatment of migraine. Theranica will continue to use its proprietary technology to develop additional solutions to other painful disorders.

For more information about the Nerivio, including Indication for Use, and Important Safety Information, visitwww.theranica.com.

FollowTheranicaonTwitterandLinkedIn.

Media Contact:Ellie HansonFinn PartnersEllie.Hanson@finnpartners.comTel: +1-929-222-8006

Theranica Contact: Ronen Jashekronenj@theranica.comTel: +972-72-390-9750

View original content:http://www.prnewswire.com/news-releases/american-headache-society-publishes-article-demonstrating-the-promise-of-remote-electrical-neuromodulation-ren-as-first-line-treatment-for-acute-migraine-relief-300954693.html

SOURCE Theranica

More here:
American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute...

‘Text neck’ injury becoming more common in kids, teens – KPAX-TV

Posted on by

OVERLAND PARK, Kan. Fall can be a busy season for sports medicine physicians as school sports ramp up.

"People come in with neck pain, they come in with upper back pain," said Dr. James Roberson of Children's Mercy Kansas City.

But those neck and back injuries often have nothing to do with sports.

"A lot of kids are kind of thinking 'oh there's no way that just looking at my phone is the problem here,' " Roberson said. "For the parents, it takes zero convincing."

The repetitive strain injury is known as "text neck."

"Sometimes I even have to lay down because my neck hurts, so I'll lay and type out a text or something," said college student Lauren Juliana.

The average head weighs 10 to 11 pounds, according to a study published in Surgical Neurology International. When you flex your head forward 30 degrees to look down at a phone, the strain on your neck is actually 40 pounds. At 60 degrees, you put 60 pounds on your neck.

"The more you do it, the more it will hurt, the harder it is to break that habit," Roberson said.

But you don't have to keep sticking your neck out to stay in touch with your friends. One easy fix is to raise your screens to eye level.

"I recommend that kids, if they're working a lot on an iPad, that they actually get a cookbook stand and set it up on a few books," Roberson said.

You can even stretch to alleviate the pain.

Roberson demonstrated one stretch in which you grab the sides of your chair then tilt your head left and right.

Another exercise he suggested is probably best to do when you're alone.

"I call it the 'derp stretch' because it makes you look kind of stupid," Roberson said with a laugh.

Start with your chin in a neutral position, then push it straight back, stretching out the back of your neck.

You can also do simple shoulder pinches to release tension. Roberson recommended doing ten repetitions of the exercises three times a day.

He's also giving parents the green light to nag their kids about the bad habit.

"It's good to tell your kids to sit up straight, better posture, move the screen up or get off the screen, go outside and play instead, which is always good advice," Roberson said.

This story was originally published by Cat Reid on KSHB.

Continue reading here:
'Text neck' injury becoming more common in kids, teens - KPAX-TV

Department of Neurology – University of Texas Medical Branch

Posted on by

A Message from the Departmental Chair

The Department of Neurology at University of Texas Medical Branch (UTMB) was established in 1973. It has a long-standing history and tradition in the practice and advancement of Clinical Neurosciences by providing the most comprehensive care to patients with neurologic illnesses from Alzheimers disease and related dementias, epilepsy, neuromuscular disorders, brain tumors, Parkinsons Disease and other movement disorders, multiple sclerosis and other autoimmune disorders, stroke as well as other acute neurologic injuries. Our department has a robust laboratory research program in the Mitchell Center that is particularly focused at advancing our knowledge of neurodegenerative disorders. Additionally, we have a highly regarded fully-accredited neurology residency training program that has served for highly successful career trajectories for our graduates.

The values of the department are aligned with the mission of UTMB to uphold integrity, demonstrate compassion and respect, embrace diversity, and strive for excellence and innovation. The departmental philosophy and vision is to optimize an organizational environment that strives for excellence in the domains of: a) clinical patient care; b) teaching, training, and mentoring medical students, residents, fellows, faculty, and staff; and c) research and scholarship. Our overall goal is to continue providing state-of-the-art care to patients with neurologic disorders, conducting and enhancing research (clinical, translational, and basic science) through interdepartmental collaborations, and training the next generation of neurologists and neuroscientists to improve diagnosis, and management of neurologic disorders and to develop more innovative therapies and strategies for the future.

Sincerely,

Anish Bhardwaj, M.D., M.B.A.,CPE, FACMPE, FACHE, FAHA, FCCM, FAAN, FANAChairman, Department of NeurologyJohn Sealy Chair of NeurologyProfessor, Neurology, Neurosurgery, Neuroscience, Cell Biology and AnatomyAssociate Dean for Faculty Affairs and Professional Development

University of Texas Medical Branch (UTMB)9.128 John Sealy Annex, Route 0539301 University BlvdGalveston, Texas 77555

Go here to read the rest:
Department of Neurology - University of Texas Medical Branch

Highlights from Day Four of the World Congress of Neurology 2019 – WFN News

Posted on by

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

It had been a fabulous 24th World Congress so far. The diversity of the speakers and delegates continue to make the world congress the premier event in neurology. The day began with an enlightening teaching course on neuro-imaging with a packed audience.

Professor John Hardy from UCL, Institute of Neurology answered the following question with a masterful lecture:What is genomics teaching us about neurodegeneration and what should we do about it?"

Prof. Hardy went on to address the issue in detail. As researchers identify the loci involved in neurodegenerative disease, they are finding that the majority of them are involved in damage response processes. He went on to propose that it is a failure in these damage response processes which underlies late-onset disease and that the resultant pathology is a marker of the type of damage response which has failed. He gave the following three examples.

He gave a detailed analysis of these and asked the question, with this insight how we could go about understanding and treating these diseases better?

The plenary gave us a ray of hope for future therapeutic potential for these disabling diseases.

Professor Tintore from Spain delivered the second plenary on multiple sclerosis. The plenary explained the evolution of diagnostic criteria for MS with McDonald 2001, 2005, 2010 and 2017 allowing earlier diagnosis with less active disease. Major advances in therapies, the importance of other factors such as lifestyle, comorbidities were discussed in detail.

Professor Reis and Wasay chaired the all-important environment and neurology symposium.

Air pollution as a major risk factor for stroke was discussed in detail. Professor Gustavo Roman discussed the environmental neurotoxins in food.

The Tournament of the minds semi-finals were extremely competitive with a tie-break between Sri Lanka and Australia. I was reminded of the 1996 world cup cricket to say the least!

Sri Lanka, Malaysia, India and Hong Kong will be fighting for the final countdown next!

See the article here:
Highlights from Day Four of the World Congress of Neurology 2019 - WFN News

Neurology Software Market Perceive Robust Expansion by: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts – New Day Live

Posted on by

Neurology Software market report forecast include the rapid expansion of current market it also shares the market prediction within a specific interval to time. To provide better perspective of the market report gives detail analysis of drivers, restraints, and trends that control the present market scenario. While classifying these segments, the specialist team of analysts has listed the relative impact of each segment for the growth of the Neurology Software market report. Neurology Software Market Report also provides independent analysis of the basics concepts of Neurology Software market.

Each segment of Neurology Software market report offers a in-depth information with qualitative and quantitative analysis of the market. Neurology Software market report also presented the value of absolute dollar opportunity for all the segments over the predicted period of 2020 to 2025.

Get Sample Report @ https://www.reportsintellect.com/sample-request/990040

Major market player included in this report are: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts

Neurology Software Market Key segments:

By type:

Advanced Neurology EMR SoftwareOther

By Application:

HospitalsCollege & Research InstitutesOther

Neurology Software Market report provides the Split of the regional market into specific countries as per your research requirements. Also Neurology Software Market report has presented the various facets of the market with a particular focus on identifying the key industry influencers.

Research report reviews Neurology Software Market Report volume in recent years. The report also emphasizes the major restraints and drivers determining the growth of the market. A report also highlights market factors like latest trends and opportunities.

Get Discounted Report @ https://www.reportsintellect.com/discount-request/990040

Details to look for in the Report:

Report offers definition and outline of Neurology Software Market with geographical dynamics that can set the Neurology Software market sky scrapping. This geographical segmentation clearly helps understand the growth and development of the Neurology Software Market in various regions from across the globe. The clarification of the historic, present, and future trends along with various competitive factors and restrictions shows the impact of these on the development of the Neurology Software market. Moreover, the report furthermore contains contributions from our exchange experts that may encourage the key players in sparing their time from the inside examination half.

Report Highlights:

1) Strategic recommendations in key business segments based on the market estimations.

2) The report provides a detailed analysis of current and future market trends to identify the investment opportunities.

3) Breakdown of the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2020 to 2025.

4) The details of the competitive landscape.

5) Top key market players and their complete profiles

6) The restraining factors coupled with the challenges being faced by the market players are included within the Neurology Software market report.

Follow this link:
Neurology Software Market Perceive Robust Expansion by: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts - New Day Live

Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028:…

Posted on by

SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- The global Nerve Repair Biomaterial Market is estimated to grow at a higher CAGR by the completion of the prediction period. The nerve repair biomaterials are utilized for reinstating damaged nerves. Injuries to the nerve take place in the lower (leg) and upper (hand and arm) edges. Biomaterials are prepared with nerve wraps, nerve protectors, nerve connectors, and nerve conduits. Owing to the high blood pressure (Diabetes), sharp or blunt trauma, the damage to the nerve happens. Nerve repair is the restoration of the nerve that is hurt. The nerve repair biomaterials are utilized to reinstate the usual working of nerves.

The bodily harm to an exterior nerve or else the incapability to appropriately rejoin nerves can result in the loss of muscle sensation/function. Nerves can be injured by numerous means. Once a nerve is cut owing to a stressful injury or surgical procedure, functionality of the nerve may possibly be compromised, affecting the nerve to no longer transmit the warning sign from and to the brain to the muscles and skin and decreasing or abolishing functionality.

The injuries to the nerve can be initiated by any direct shock, for example an impact due to the drop or else due to traction wounds from the accidents of motor vehicle or else sharp disruption, for example straight slashes from a knife. Harm to a nerve can halt warning sign to and from the brain. Operating nerve restoration comprises the investigation of the damaged nerve and the elimination of damaged soft tissue from the nerve terminations. Nerve Repair Biomaterial products are utilized over surgical interferences to re-establish usual function in nerves.

The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation. The demand for nerve repair biomaterials is growing in the hospitals. Owing to the growing number of elderly people and increasing number of nerve surgeries & nerve injuries, the demand for nerve repair biomaterials is also growing in the ambulatory trauma centers. These centers are tracking the hospitals.

Download PDFto know more details about "Nerve Repair Biomaterial Market" report 2028.

Drivers

Growth in the aged populace, greater frequency of nerve injuries, and increasing occurrence of infants having nervous complaints is estimated to perform such as a motivator for the development of the Nerve Repair Biomaterial Market.

Restraints

Absence of consciousness in the emerging areas is likely to restrain the development of the Nerve Repair Biomaterial Market.

Classification

The global Nerve Repair Biomaterial Market can be classified by End Users, Type of Injury, Nerve Protection, and Type of Product. By End Users, it can be classified as Ambulatory Trauma Centers, Hospital, and Clinics. By Type of Injury, it can be classified as Group Fascicular Repair, Epineural Nerve Repair, Perineural Nerve Repair. By Nerve Protection, it can be classified as Nerve Wrap, Nerve Protectors. By Type of Product, it can be classified as Nerve Graft, Nerve Repair.

Regional Lookout

By Region the global Nerve Repair Biomaterial Market can be classified as North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa.

Companies

Some of the important companies for Nerve Repair Biomaterial Market are Neurotex, Polyganics, Axo Gen Inc., Collagen Matrix, Synovis Micro Companies Alliance, Inc., Checkpoint Surgical, Inc., Stryker Corporation, and Collagen Matrix, Inc.

Access 109 page research report with TOC on "Nerve Repair Biomaterial Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/2013-2028-report-on-global-nerve-repair-biomaterial-market

This report provides detailed historical analysis of global market for Nerve Repair Biomaterial from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Nerve Repair Biomaterial market.

Browse reports of similar category available with Radiant Insights, Inc.:

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:Michelle Thoras.Corporate Sales SpecialistRadiant Insights, Inc.Phone: +1-415-349-0054Toll Free: 1-888-928-9744Email: [emailprotected] Web: https://www.radiantinsights.com/Blog: https://radiantinsightsinc.blogspot.com/

SOURCE Radiant Insights, Inc.

Read the rest here:
Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028:...

Loss of Smell, Confusion, Strokes: Does COVID-19 Target the Nervous System? – Discover Magazine

Posted on by

For many people, a sudden loss of smell is the first sign that somethings wrong. One gentleman said he realized it with hand sanitizer, says Carol Yan, a rhinologist at the University of California, San Diego. All of a sudden it was like water to him. The loss of smell, or anosmia, is such a common symptom of Covid-19 that the US Centers for Disease Control and Prevention recently added it to its official list.

The loss of smell (or taste) is one of many emerging hints that the SARS-CoV-2 virus may affect the nervous system. Physicians around the world have documented neurological symptoms in a significant fraction of Covid-19 patients. Some patients have experienced headaches, dizziness and other relatively minor symptoms, while others have had more serious problems like confusion and impaired movement, and even seizures and strokes.

Such reports have been circulating on message boards used by physicians, and they are just now making their way into the peer-reviewed scientific literature. Nobody knows at this point how widespread neurological symptoms are, nor the extent to which they contribute to the overall clinical picture for Covid-19.

Another huge unknown is whether SARS-CoV-2 can attack the nervous system directly by infecting neurons as rabies and a number of other viruses do or cause neurological symptoms indirectly, by triggering rampant inflammation or blood clotting.

These are critical questions, says Samuel Pleasure, a neuroscientist and neurologist at the University of California, San Francisco. For a small number of patients, neurological symptoms seem to be the earliest or even the only indicator of infection. For others, lingering or post-infection neurological problems could complicate recovery. We dont know whether or not thats going to be the case yet, but its an important unanswered question, says Pleasure.

Reports of lost taste and smell often in the absence of the kind of nasal congestion that interferes with olfaction with the common cold have been circulating for months. In one of the first peer-reviewed journal articles on the subject, Yan and colleagues describe results from an online survey of 262 patients in the UCSD hospital system. Slightly more than two-thirds of those who tested positive for Covid-19 experienced taste and smell deficits.

The deficits werent subtle, Yan says. Most people went from like a ten to zero. Fortunately, as patients get better, they seem to be regaining their sensory abilities, usually within a few weeks, the team reported April 12 in the International Forum of Allergy & Rhinology.

In an April 22 letter to the Journal of the American Medical Association, physicians reported a similar prevalence of anosmia in Covid-19positive patients at a regional hospital in Treviso, Italy. For 12 percent of these patients, the loss of smell occurred prior to other symptoms. For 3 percent, it was the only symptom they ever experienced.

Such reports have prompted several medical associations for ear, nose and throat specialists to issue statements urging physicians to consider anosmia as a potential screening tool for Covid-19 and to advise patients who experience a sudden loss of smell to consider self-isolating.

In theory, SARS-CoV-2 could get into the brain through several routes. The virus could enter the brain through the bloodstream if it can get past the cellular defense wall known as the blood-brain barrier. Or it could conceivably infect olfactory neurons in the nasal cavity or peripheral nerves elsewhere in the body and hitchhike into the brain along their axons. Scientists don't yet know which, if any, of these routes the virus can take.

Yan speculates that the presence of anosmia could turn out to be a a clue to how the disease might progress. She notes that most patients in her study had relatively mild cases of Covid-19 most were not hospitalized, and none required a ventilator to help them breathe. In contrast, other researchers have found a lower prevalence of anosmia among sicker patients. One possibility, Yan says, is that anosmia is more common in mild cases because the virus mostly stays in the nasal cavity. In more severe cases, it infiltrates the lungs, causing more dangerous respiratory symptoms but fewer sensory deficits. At this point its just a hypothesis, but its one she and her colleagues plan to investigate.

Preliminary evidence suggests that SARS-CoV-2 does not directly infect olfactory neurons, the odor-detecting cells at the top of the nasal cavity, at least by its usual route. In April, two RNA sequencing studies one led by researchers at Harvard, another by a group in Switzerland concluded that olfactory neurons do not make two key proteins, including the ACE2 receptor, used by the virus to break into cells. (The findings were posted before publication on the website bioRxiv and have not yet been peer-reviewed.)

However, neighboring support cells do appear to produce these proteins. The sudden loss of smell in Covid-19 patients could result from the virus infecting these support cells and then either causing local inflammation or disrupting the cells role in maintaining the balance of ions that olfactory neurons need to function properly, says neuroscientist Sandeep Robert Datta, who led the Harvard study.

Reports of other neurological symptoms in Covid-19 patients have emerged from China, France and elsewhere. In one of the first studies, doctors in Wuhan, China, reported April 10 in JAMA Neurology that of 214 patients hospitalized there between mid-January and mid-February, slightly more than a third experienced neurological symptoms that ranged from dizziness and headache to (less commonly) impaired consciousness, movement difficulties and seizures.

In an April 15 letter to the New England Journal of Medicine, doctors in Strasbourg, France, reported an even higher prevalence of neurological symptoms in a group of patients there: 84 percent experienced symptoms that included prominent agitation and confusion and alterations to reflexes and muscle contractions that suggested neurological problems in the brain.

The role SARS-CoV-2 plays in such symptoms remains an open question, especially for sicker patients who are likely to have low oxygen levels or preexisting conditions that could cause the same symptoms, says Pleasure, who cowrote an editorial on the Chinese study. The kinds of symptoms that were more common in the more severe patients could be happening in part because the patients are so sick, not because they have Covid-19, he says.

There were scattered reports of neurological problems with SARS and MERS, respiratory syndromes caused by coronaviruses related to the one causing the current pandemic, but the prevalence of such symptoms wasnt well documented. There seem to be more such reports with Covid-19, but that could be because so many more people have been affected in total, not necessarily that those symptoms occur in a higher proportion of patients, says Stanley Perlman, an infectious disease researcher at the University of Iowa Carver College of Medicine. More than four million people (and counting) have been infected in the current pandemic, compared with about 8,000 for SARS and 2,500 for MERS.

Some researchers have speculated that SARS-CoV-2 may invade the nervous system and suppress respiratory centers in the brain, contributing to the severity of breathing problems. So far theres no direct evidence for that, but scientists say its not out of the question.

Pierre Talbot, a virologist at the Armand-Frappier Sant Biotechnologie Research Centre near Montreal, has long argued that coronaviruses could be an underestimated threat to the nervous system. In experiments with mice and cultured human neurons, his group has found evidence that a human coronavirus called OC43, a frequent cause of the common cold, can travel from the respiratory tract to the nervous system. In 2016, the researchers reported finding the virus in brain tissue from an 11-month-old boy who died of encephalitis, or inflammation of the brain. Coronaviruses can do much more than cause respiratory diseases, Talbot says. The neurological aspects of Covid-19 are not surprising.

In experiments with genetically engineered mice, Perlman and his colleagues previously found that SARS and MERS can infect olfactory neurons and travel along their axons to the brains olfactory bulb. From there, the viruses spread quickly throughout the brain. His lab plans to repeat those experiments with SARS-CoV-2, but he cautions that mouse experiments may not replicate what a virus does in people in real-world conditions. And the new virus may act differently as suggested by the bioRxiv studies that showed that the virus likely cant infect the human olfactory neurons using its usual tactics.

Many viruses, Perlman says, have evolved other ways of getting into the nervous system including tricks for slipping past the guardian cells of the blood-brain barrier, which normally keep blood-borne pathogens out of the brain. Its still far too early to know all that SARS-CoV-2 is capable of. This virus is teaching us so much, Perlman says. I wouldnt draw any conclusions. Experiments that might help resolve the issue, such as tests on spinal fluid or autopsied brain tissue from Covid-19 patients, have been delayed by safety concerns.

Loss of smell has been reported in many Covid-19 patients. Inhaled air comes into contact with olfactory neurons at the top of the nasal cavity, raising the possibility that SARS-CoV-2 could infect the neurons and travel into the olfactory bulb, a part of the brain. But preliminary work suggests the virus may not be able to infect olfactory neurons. Instead, it may infect the adjacent supporting and stem cells in the olfactory epithelium.

Even if SARS-CoV-2 does not directly attack the nervous system, it could cause neurological problems indirectly. One way it could do this is through rampant inflammation known as a cytokine storm. In a case study published in Radiology, doctors in Detroit reported brain scan abnormalities indicative of a rare encephalopathy linked to cytokine storms in an airline worker in her mid-50s who tested positive for the virus. Another concern is reports of mysterious abnormalities in blood clotting in young and middle-aged Covid-19 patients that may increase the risk of stroke.

Some secondary effects could take time to develop. In an April 17 letter to the New England Journal of Medicine, Italian doctors described five Covid-19 patients who developed GuillainBarr syndrome, a condition that starts with weakness and tingling in the extremities and can progress to more serious movement difficulties. GuillainBarr syndrome occurs after infection, such as with Campylobacter bacteria, a frequent cause of food poisoning, when antibodies made by the immune system to fight the bacteria end up attacking the nervous system instead.

If the same thing happens with SARS-CoV-2, Pleasure says, doctors may see a wave of post-infection neurological conditions like GuillainBarr in the months ahead. As with nearly everything related to Covid-19, the full impact wont be known for some time.

This article originally appeared inKnowable Magazine, an independent journalistic endeavor fromAnnual Reviews. Read the original storyhere.

Original post:
Loss of Smell, Confusion, Strokes: Does COVID-19 Target the Nervous System? - Discover Magazine

Value of Neurologic Disorders Therapeutics Market Predicted to Surpass US$ by the of 2035 2018 2028 Dagoretti News – Dagoretti News

Posted on by

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Neurologic Disorders Therapeutics Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Neurologic Disorders Therapeutics market. We have also provided absolute dollar opportunity and other types of market analysis on the global Neurologic Disorders Therapeutics market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Neurologic Disorders Therapeutics market. All findings and data on the global Neurologic Disorders Therapeutics market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Neurologic Disorders Therapeutics market available in different regions and countries.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6000&source=atm

The authors of the report have segmented the global Neurologic Disorders Therapeutics market as per product, application, and region. Segments of the global Neurologic Disorders Therapeutics market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Neurologic Disorders Therapeutics market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Drivers and Restraints

There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. One of the key driving factors is the increasing advances in the diagnosis of the different neurodegenerative indications. This has helped in increasing the demand for new therapeutics to effectively treat such neurodegenerative disorders. The early determination such disorders is difficult due to its complex nature of such disorders, lack of efficient diagnostics, and its fast progression. This has naturally helped in driving the activities of research and development for more effective treatment. Governments across the globe are also helping research institutes by allotting more funds for the development of new neurologic disorder therapeutics.

Global Neurologic Disorders Therapeutics Market: Geographical Outlook

The global neurologic disorders therapeutics market is primarily divided into five key regions viz. North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. Of these, the global neurologic disorders therapeutics market is primarily dominated by North America region. This is because of the high aging population in the region, advancements in technology, and highly developed healthcare infrastructure.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6000&source=atm

Neurologic Disorders Therapeutics Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Neurologic Disorders Therapeutics Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Neurologic Disorders Therapeutics Market in South, America region is also expected to grow in near future.

The Neurologic Disorders Therapeutics Market report highlights is as follows:

This Neurologic Disorders Therapeutics market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Neurologic Disorders Therapeutics Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Neurologic Disorders Therapeutics Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Neurologic Disorders Therapeutics Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=6000&source=atm

See original here:
Value of Neurologic Disorders Therapeutics Market Predicted to Surpass US$ by the of 2035 2018 2028 Dagoretti News - Dagoretti News

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR | TCRM – Dove Medical Press

Posted on by

Marco Luigetti,1,2 Angela Romano,2 Andrea Di Paolantonio,2 Giulia Bisogni,3 Mario Sabatelli2,3

1Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Universit Cattolica del Sacro Cuore, Rome, Italy; 3Centro Clinico NEMO Adulti, Rome, Italy

Correspondence: Marco LuigettiNeurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A Gemelli 8, Rome 00168, ItalyTel +39-06-3015 4435Fax +39-06-3550 1909Email mluigetti@gmail.com

Abstract: Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (formerly known as Familial Amyloid Polyneuropathy) is a rare disease due to mutations in the gene encoding transthyretin (TTR) and characterized by multisystem extracellular deposition of amyloid, leading to dysfunction of different organs and tissues. hATTR amyloidosis represents a diagnostic challenge for neurologists considering the great variability in clinical presentation and multiorgan involvement. Generally, patients present with polyneuropathy, but clinicians should consider the frequent cardiac, ocular and renal impairment. Especially a hypertrophic cardiomyopathy, even if usually latent, is identifiable in at least 50% of the patients. Therapeutically, current available options act at different stages of TTR production, including synthesis inhibition (liver transplantation and/or gene-silencing drugs) or tetramer TTR stabilization (TTR stabilizers), increasing survival at different disease stages.

Keywords: amyloid, polyneuropathy, clinical care, therapy, transthyretin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:
Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR | TCRM - Dove Medical Press

Acute stroke response is again close at hand in Westerly area – The Westerly Sun

Posted on by

WESTERLY "Time is brain" is a phrase used by doctors to stress the importance of rapid care for stroke patients.

"If someone waits too long, unfortunately, there may be less that we can do to help them," Dr. Ryan Carter, who chairs the Westerly Hospital Emergency Department, said during a recent interview.

With the importance of a speedy response in mind, Westerly Hospital, after completing a long certification process, is once again able to accept and provide initial treatment to all but the most severe stroke patients. The service went into effect on Jan. 1.

For about the previous 10 years, Rhode Island Department of Health regulations required stroke patients to be treated at either primary or comprehensive stroke centers. But now a third category acute stroke ready has been established. Westerly Hospital gained the certification as an acute stroke ready facility from the Joint Commission on Accreditation of Healthcare Organizations last February, and the state's emergency medical services protocols were updated more recently to reflect the new certification category.

The certification allows smaller and rural hospitals to demonstrate their ability to comply with standards of care for the initial treatment of stroke patients when prompt action and proper medications can save lives and limit the long-term disabling effects of strokes.

As an acute stroke ready facility, Westerly Hospital has shown it has the infrastructure and capability to care for acute strokes, including administration of intravenous thrombolytic therapy. Most acute stroke patients will be transferred to a primary or comprehensive stroke center that would provide ongoing care and / or endovascular procedures after initial stabilization in Westerly.

To gain the acute stroke ready certification, the hospital had to demonstrate four basic capabilities: access to trained medical personnel who are able to assess stroke patients; access to a neurologist; quick access to a CAT scan; and a system in place to deliver the clot busting intravenous thrombolytic therapy.

"Because time is brain we need to get this medication to these patients as quick as possible," said Lisa Bedard, stroke and neurodiagnostics manager at Westerly Hospital.

The lack of in-house neurologists had previously been an obstacle for Westerly Hospital, but the evolution of telemedicine and the hospital's acquisition by Yale New Haven Health in 2016 allow Yale New Haven neurologists who specialize in stroke care to assess patients remotely through the use of a telecart. The device includes an audio component and a high definition camera that enable neurologists in New Haven to see and hear patients as if they were in the same room. "The doctor can see anything that I can see," said Marlea Bergeson, a registered nurse and clinical coordinator of the Westerly Hospital Emergency Department.

When assessing whether a patient has suffered a stroke, doctors look for both overt and subtle signs such as facial droop, facial asymmetry, whether a patient's pupils are equal, and quality of speech. Neurologists in New Haven are notified as soon as Westerly Hospital receives a potential stroke patient and can see CAT scan results immediately in real time before patients even leave the scan room.

In addition to being certified as an acute stroke ready facility, the hospital worked with the Rhode Island Department of Health's Ambulance Advisory Board to get protocols changed to allow for the acceptance and treatment of stroke patients.

"That was a big hurdle to get over because we had to convince them so everyone knows what acute stroke ready hospitals are," said Tim Law, chief paramedic for Westerly and L+M hospitals and a member of the Rhode Island Stroke Task Force.

With the new protocols in place, patients who suffer strokes in the Westerly region now stand a greater chance of receiving care quickly. Rather than a 20 minute ride to New London or a slightly longer trip to Wakefield, they can be treated at Westerly Hospital.

"The advantage to that is time. Somebody in Westerly will get here and get imaged and treated more quickly than being transported to L+M or South County Hospital and that is advantageous from a health point of view," said Dr. William Conlin, an emergency medicine physician at Westerly Hospital.

Because each passing minute is critical, when paramedics respond to a 911 call they score a patient's symptoms to determine the type of facility a patient should go to. More severe symptoms require treatment at a primary or comprehensive stroke center.

Ralph Miro, director of nursing for the Westerly Hospital Emergency Department, stressed the importance of public awareness of stroke symptoms. He recommended using acronym FAST: face drooping, arm weakness, speech difficulty, and time to call 911.

"The tendency for many families is to put the patient in the car and bring them in that manner, but actually what they should do is access 911 and ensure that they have highly trained medical personnel to bring them in as soon as possible," Miro said.

Strokes occur when a blood vessel that carries oxygen and nutrients to the brain is either blocked by a clot or bursts.When that happens, part of the brain cannot get the blood and oxygen it needs.

Bedard thanked state Sen. Dennis Algiere, R-Westerly, for his help in developing new legislation that allows for the recognition of acute stroke ready hospitals in Rhode Island.

Read the original here:
Acute stroke response is again close at hand in Westerly area - The Westerly Sun

Rare Neurological Disease Treatment Market To Exceed Revenues Worth US$ By The End Of 2017 2025 Dagoretti News – Dagoretti News

Posted on by

In 2019, the market size of Rare Neurological Disease Treatment Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Rare Neurological Disease Treatment .

This report studies the global market size of Rare Neurological Disease Treatment , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=3257&source=atm

This study presents the Rare Neurological Disease Treatment Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Rare Neurological Disease Treatment history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Rare Neurological Disease Treatment market, the following companies are covered:

Market Potential

Genetically engineered to model a predominantly, an inherited, and a rare neurological human disease called ataxia telangiectasia (AT), the ExeGen ATM MiniSwine has been cleared for commercial use by the FDA. In regard to the model, the FDA has exercised enforcement discretion. This powerful investigational platform by Exemplar could be offered to drug developers, researchers, and scientists looking to develop innovative therapeutics and define disease mechanisms to address ATs pathologies. It is expected to enable improved predictive efficacy and superior translational research.

Global Rare Neurological Disease Treatment Market: Regional Outlook

North America is envisaged to rake in a handsome demand for rare neurological disease treatment because such diseases are considered to be a serious health concern. However, some researchers say there are only a few people affected by rare neurological conditions. The demand for rare neurological disease treatment could be high due to lack of sufficient options and complications of the disease. Moreover, healthcare and government institutions in the region are collaborating to develop a strong research network for the purpose of allowing advancement in rare disease treatment, enrollment in studies and trials, and data sharing.

Global Rare Neurological Disease Treatment Market: Competition

Players operating in the international rare neurological disease treatment market are profiled based on their share, recent developments, finance, business strategies, and company portfolio. Some of the popular names of the industry are Teva Pharmaceutical Industries Limited, Medtronic Plc, and Johnson & Johnson.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=3257&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Rare Neurological Disease Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Rare Neurological Disease Treatment , with price, sales, revenue and global market share of Rare Neurological Disease Treatment in 2017 and 2019.

Chapter 3, the Rare Neurological Disease Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Rare Neurological Disease Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=3257&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Rare Neurological Disease Treatment market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Rare Neurological Disease Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Visit link:
Rare Neurological Disease Treatment Market To Exceed Revenues Worth US$ By The End Of 2017 2025 Dagoretti News - Dagoretti News

Neurology Software Market to Witness Rapid Growth by 2025 | Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics. Dagoretti News…

Posted on by

The Neurology Software market has been changing all over the world and we have been seeing a great growth In the Neurology Software market and this growth is expected to be huge by 2025. The growth of the market is driven by key factors such as manufacturing activity, risks of the market, acquisitions, new trends, assessment of the new technologies and their implementation. This report covers all of the aspects required to gain a complete understanding of the pre-market conditions, current conditions as well as a well-measured forecast.

The report has been segmented as per the examined essential aspects such as sales, revenue, market size, and other aspects involved to post good growth numbers in the market.

Top Companies are covering This Report:- Epic, Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics, Greenway Health, Allscripts, Kareo, Advanced Data Systems, NueMD, etc.

Get Sample PDF [emailprotected] https://www.reportsintellect.com/sample-request/900523

Description:

In this report, we are providing our readers with the most updated data on the Neurology Software market and as the international markets have been changing very rapidly over the past few years the markets have gotten tougher to get a grasp of and hence our analysts have prepared a detailed report while taking in consideration the history of the market and a very detailed forecast along with the market issues and their solution.

The given report has focused on the key aspects of the markets to ensure maximum benefit and growth potential for our readers and our extensive analysis of the market will help them achieve this much more efficiently. The report has been prepared by using primary as well as secondary analysis in accordance with porters five force analysis which has been a game-changer for many in the Neurology Software market. The research sources and tools that we use are highly reliable and trustworthy. The report offers effective guidelines and recommendations for players to secure a position of strength in the Neurology Software market. The newly arrived players in the market can up their growth potential by a great amount and also the current dominators of the market can keep up their dominance for a longer time by the use of our report.

Neurology Software Market Type Coverage:

Advanced Neurology EMR Software, Other, etc.

Neurology Software Market Application Coverage:

Hospitals, College & Research Institutes, Other, etc.

Market Segment by Regions, regional analysis covers

North America (United States, Canada, Mexico)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Europe, Middle East and Africa (Germany, France, UK, Russia and Italy, Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/900523

Competition analysis

As the markets have been advancing the competition has increased by manifold and this has completely changed the way the competition is perceived and dealt with and in our report, we have discussed the complete analysis of the competition and how the big players in the Neurology Software market have been adapting to new techniques and what are the problems that they are facing.

Our report which includes the detailed description of mergers and acquisitions will help you to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Why us:

Reasons to buy:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

[emailprotected]Phone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

See the article here:
Neurology Software Market to Witness Rapid Growth by 2025 | Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics. Dagoretti News...

Auburn is home to new neurology office – Midland Daily News

Posted on by

Jon Becker, For the Daily News

Photo: Michael David-Lorne Jordan/David-Lorne Photographic

Auburn is home to new neurology office

Auburn is now the site of a new neurology office led by the former chairman of neurosciences at MidMichigan Regional Medical Center-Midland.

Dr. Gregory Dardas, now with Owosso-based Memorial HealthCare, is leading the Auburn practice that was unveiled to the public during a recent ribbon-cutting ceremony.

The Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, located at 4600 Garfield Road, is up and running in a building that formerly housed a temporary employment service agency and civil engineering firm.

"They completely renovated the entire building and have converted it into state-of-the art medical offices," said Paul Wasek, Williams Township supervisor. "Any kind of specialty field that the medical community brings to this area is a welcome sight. It's a good sign that a need is being met."

The Auburn location currently has five employees, including the addition of a new EMG certified technician, who is expected to join the medical team after the first of the year.

"Opening an office for our neurological practice in the Auburn area gives Memorial Healthcare the opportunity to expand our geographical footprint in a way that makes our world-class treatment of complex neurological disorders more accessible to patients across Mid-Michigan," said Brian Long, president & CEO of Memorial Healthcare. "This office will compliment Memorial Healthcare's existing neurological services in the Owosso, Saginaw, Bay City and Midland areas."

Dardas, said officials, is well-suited to lead this specialty practice that will treat a wide variety of neurological conditions.

"Dr. Dardas brings a wealth of knowledge and experience in treating Parkinson's disease, dementia, headaches, peripheral neuropaths, myopathies and neuromuscular diseases to Memorial Healthcare," said Dr. Rany Aburashad, chief of neurology and director of multiple sclerosis at Memorial Healthcare. "This experience will further elevate our ability to provide cutting-edge, industry-leading neurological treatment to our patients."

While Dardas heads up the Auburn practice, he is supported by Memorial's broader team that includes Aburashed, who is credited for being the first in the United States to utilize neurofilament light chain technology testing for MS patients in a clinical setting.

"Patients from all over the world seek out treatment and care for neurological conditions, and we continue to attract the top doctors in other specialty areas whose vision for patient care aligns with ours," said Long. "When patients want the best care, regardless of ailment, they come to Memorial Healthcare."

The new Auburn practice in Williams Township represents another move by Memorial to expand its presence in small communities throughout Mid-Michigan.

"At Memorial Healthcare, our core mission is to provide world class medical treatment combined with small town values," Long said, noting its flagship facility in Owosso is developing a new $30 million Community Wellness Center and also is opening a new location in St. John's. "It's this patient-centric vision that is driving our ambitious growth and development plans."

"Having these types of top-notch medical services available right here in our community is huge," Wasek said. "Our community is aging. People are living longer."

Continue reading here:
Auburn is home to new neurology office - Midland Daily News

Creating the technology to disrupt seizures and addiction – SciTech Europa

Posted on by

Novela Neurotech, a company developing AI-powered wireless, smart neural interface systems, joins Canadas Creative Destruction Lab to adjust its health technologies to the needs of patients with difficult neurological disorders.

Our core mission is to foster a new era of neurological treatments by focusing on their electrical signalling within the brain. Rather than flooding the brain with chemical drugs, we aim to precisely interfere with aberrant neural signalling that leads to disorders.

To that end, we are developing a platform that accelerates these technologies at multiple stages, including pre-clinical discovery, clinical trials and post-market, real-world evidence data collection, says Ray Iskander, Cofounder and CEO of Novela Neurotech.

Depression, addiction, epilepsy and chronic pain plague millions of people globally, yet traditional pharmaceutical solutions fail in approximately 30 percent of cases. The root causes of these mental disorders are buried within the electrical communications of complex brain circuits.

By listening in on these brain communications and decoding their messages using neural interfaces, it may be feasible to target and disrupt the brains signals that lead to unsafe neurological episodes, such as seizures or cravings, with a burst of electrical stimulation.

Electrical stimulators, such as spinal cord stimulators for back pain, have been around for decades, but theyre not very adaptable and can only stimulate in a few forms.

We are bringing the power of AI to neural stimulators, miniaturising them into seamless interfaces with the brain, says Dr. Salam Gabran, Technical Cofounder of Novela Neurotech.

The complexity of the brain makes it extremely difficult to record from and decode messages in specific neural circuits. For the past decade, Novela Neurotech has been working on a wireless, bi-directional and flexible interface that is designed to sit within the brain and silently monitor for disease-causing electrical signals.

On 11 December, 2019 Novela Neurotech showcased its production-ready neural interface that miniaturises a roomful of equipment into a device smaller than the tip of a finger at Creative Destruction Lab, a seed-stage program that supports massively-scalable companies rooted in translational science and technology.

The device, made through state-of-the-art microfabrication technologies, is just one aspect of Novelas Neureka platform to accelerate next-generation neurological treatments throughout the entire therapeutic developmental process. During preclinical discovery stage, the software ecosystem promotes data sharing and collaboration between neuroscientists, data scientists and neurologists. Due to the brains complexity and the difficulties for a single institution to gather enough data for mining, a collaborative platform is tantamount for accelerating this initial discovery phase while dramatically reducing research costs.

Depression, addiction, and chronic pain remains some of todays hardest disorders to manage and treat. Its clear that neurological treatments require new therapeutic avenues in addition to pharmaceuticals.

Were thankful for being selected for the Creative Destruction Lab and collaborating with their strong network of accomplished mentors and investors to further bring our technologies, inventions and insights to help millions in need, says Iskander.

Read more here:
Creating the technology to disrupt seizures and addiction - SciTech Europa

Interventional Neurology Device Market (2019-2026) | Size, Growth Trends, Future Prospects, And Their Contribution to the Global Industry Scenario |…

Posted on by

The Interventional Neurology Device market study offers an extensive analysis of the trends observed in the growth against the global setting. This report delivers conclusive information relating to various aspects of the market viz. the commercial applications, size of the industry and speculated profit margin over the planned timeline. It also demonstrates the competitive landscape with an emphasis on the leading producers in the forecast years, highlighting their product portfolios and regional business ventures.

Global Interventional Neurology Device Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Interventional Neurology Device industry.

Download FREE sample copy of Interventional Neurology Device market report @ https://www.marketexpertz.com/sample-enquiry-form/55033

The global market size of Interventional Neurology Device is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2026 with a CAGR of XX% from 2019 to 2026.

This report on the Interventional Neurology Device market delivers a cumulative synopsis of the speculations of this business, overall, along with an evaluation of its segmentations. It predicts the Interventional Neurology Device market to advance as one of the most profitable verticals, generating massive revenue by the end of the forecast years, exhibiting a sizable growth rate over the calculated period. The opportunities for growth and expansion that are prominent in the sector as well as the geographical coverage of the industry have also been investigated by the report.

A synopsis of the fundamentals of this report:

Identifying the basic business drivers, challenges, and tactics adopted:

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price@ https://www.marketexpertz.com/discount-enquiry-form/55033

Outlining the competitive landscape of the Interventional Neurology Device market:

A brief outlook of the key companies in the Interventional Neurology Device market, focusing on companies such as

MedtronicJohnson and JohnsonTerumo CorporationPenumbra, Inc.Merit Medical Systems, IncW.L. Gore & AssociatesMicroport Scientific CorporationMedikit Co., Ltd.StrykerOthers

These particulars additionally consist of a basic summary of the corporations, company profile, and the product portfolio of the company in focus.

The report analyses the gathered information relating to the profits accrued, sales, gross margins, price patterns, revenue and updates on the activities of the company.

Most important types of Interventional Neurology Device products covered in this report are:

Embolization & coilingNeurothrombectomy Devices

Most widely used downstream fields of Interventional Neurology Device market covered in this report are:

Treatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

Browse complete Interventional Neurology Device report description And Full TOC @ https://www.marketexpertz.com/industry-overview/global-interventional-neurology-device-market

In this study, the years considered to estimate the market size of Interventional Neurology Device are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2026

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders:

Why Choose Market Expertz?

Request customized copy of Interventional Neurology Device report @ https://www.marketexpertz.com/customization-form/55033

See the original post here:
Interventional Neurology Device Market (2019-2026) | Size, Growth Trends, Future Prospects, And Their Contribution to the Global Industry Scenario |...